Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Transplantation

• Publication date

  2001-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1034/j.1399-0012.2001.150607.xPMID 11737117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs.

  2000cited by this paper
• The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection.

  2000cited by this paper
• The Effect of Renal Insufficiency on Mycophenolic Acid Protein Binding

  1999cited by this paper
• Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels.

  1999cited by this paper
• The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.

  1999cited by this paper
• Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.

  1999cited by this paper
• Non-transplant uses of mycophenolate mofetil.

  1999cited by this paper
• Low systemic exposure to tacrolimus correlates with acute rejection.

  1999cited by this paper
• Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring.

  1998cited by this paper
• Therapeutic monitoring of mycophenolic acid. A consensus panel report.

  1998cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998cited by this paper
• Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients.

  1998cited by this paper
• The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

  1998cited by this paper
• Therapeutic monitoring of mycophenolic acid: A consensus panel report

  1998cited by this paper
• Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.

  1998cited by this paper
• Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration.

  1997cited by this paper
• A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity.

  1996cited by this paper
• Mycophenolate mofetil in liver transplantation

  1996cited by this paper
• Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.

  1996influential reference
• Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment

  1996cited by this paper
• Pharmacokinetics of mycophenolate mofetil (RS61443): a short review.

  1996cited by this paper
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

  1996cited by this paper
• Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma.

  1996cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan.

  1995cited by this paper
• Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

  1995cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

  1995cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection

  1995cited by this paper
• Determination of a new immunosuppressant, mycophenolate mofetil, and its active metabolite, mycophenolic acid, in rat and human body fluids by high-performance liquid chromatography.

  1994cited by this paper
• Mycophenolate mofetil, a rationally designed immunosuppressive drug

  1993cited by this paper
• Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation.

  1992cited by this paper
• Free Drug Concentration Monitoring in Clinical Practice

  1986cited by this paper
• Free drug concentration monitoring in clinical practice. Rationale and current status.

  1986cited by this paper
• Protein Binding and Kinetics of Drugs in Liver Diseases

  1977cited by this paper

• Limited sampling strategy to predict free mycophenolic acid area under the concentration–time curve in paediatric patients with nephrotic syndrome

  2023cites this paper
• Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: Exploratory analysis of the effects of clinical factors and gene variants

  2022cites this paper
• Effects of Corticosteroid Treatment on Mycophenolic Acid Exposure in Renal Transplant Patients—Results From the SAILOR Study

  2021cites this paper
• Monitoring der immunsuppressiven Therapie

  2020cites this paper
• Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion

  2020cites this paper
• Impacto del polimorfismo MRP2 24ct en el trasplante renal en tratamiento con ácido micofenólico: farmacocinética y repercusión clínica

  2019cites this paper
• Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation

  2016cites this paper
• What is the intrapatient variability of mycophenolic acid trough levels?

  2015cites this paper
• Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?

  2014cites this paper
• Lights and Shadows of the Actual European Guidelines on Bioanalytical Method Validation: The Case of Raltegravir

  2014cites this paper
• Biomolekylære markører hos de novo nyretransplanterte pasienter – Endringer i metabolsk aktivitet, puriner og IMPDH-kapasitet i ex vivo-aktiverte lymfocytter.

  2014influential citation
• Mathematical modeling of the in vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes.

  2014cites this paper
• Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention

  2014cites this paper
• Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation

  2014cites this paper
• Mycophenolic Acid pharmacokinetics early after kidney transplant.

  2013cites this paper
• Pharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients.

  2013cites this paper
• Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC‐MPS) co‐administered with cyclosporine in the early‐phase post‐kidney transplantation

  2012cites this paper
• ADVANCED MMF MONITORING STRATEGY IN LIVER TRANSPLANTATION IN PRESENCE OR ABSENCE OF CALCINEURIN INHIBITORS

  2012cites this paper
• Pharmacokinetics and Pharmacodynamics of Mycophenolate in Patients After Renal Transplantation

  2012cites this paper
• Renal Transplantation - Updates and Advances

  2012cites this paper
• Identification of the Genotype – Phenotype Correlation in the Inosine Monophosphate Dehydrogenase Enzyme

  2012cites this paper
• Monitoring immunosuppression after liver transplantation : development of individualized Bayesian limited sampling monitoring

  2012cites this paper
• Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

  2011cites this paper
• Mycophenolic acid agents: is enteric coating the answer?

  2011cites this paper
• Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase

  2011cites this paper
• Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial

  2010influential citation
• Mycophenolic Acid Exposure in High- and Low-Weight Renal Transplant Patients After Dosing With Mycophenolate Mofetil in the Opticept Trial

  2010cites this paper
• Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.

  2010cites this paper
• Sustained Renal Response to Mycophenolate Mofetil and CNI Taper Promotes Survival in Liver Transplant Patients with CNI-Related Renal Dysfunction

  2010cites this paper
• Authorsʼ Reply to Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy

  2010cites this paper
• Variability in the pharmacokinetics of mycophenolic acid: Implications for therapeutic drug monitoring

  2010influential citation
• Therapeutic monitoring of mycophenolate in transplantation: is it justified?

  2009cites this paper
• Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.

  2009cites this paper
• Anemia after kidney transplantation.

  2009cites this paper
• Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients.

  2009cites this paper
• Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von Mycophenolsäure in der Transplantationsmedizin: Wo stehen wir?

  2009cites this paper
• New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation

  2009cites this paper
• A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine

  2009cites this paper
• Pharmacokinetics of Mycophenolic Acid in Live Donor Liver Transplant Patients vs Deceased Donor Liver Transplant Patients

  2008cites this paper
• Pharmacokinetics of Tacrolimus in Living Donor Liver Transplant and Deceased Donor Liver Transplant Recipients

  2008cites this paper
• Utility of monitoring mycophenolic acid in solid organ transplant patients.

  2008influential citation
• Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review

  2008cites this paper
• Development of a CE method for the determination of mycophenolic acid in human plasma: A comparison with HPLC

  2007cites this paper
• Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma.

  2007cites this paper
• Pharmacokinetics of Mycophenolic Acid and Estimation of Exposure Using Multiple Linear Regression Equations in Chinese Renal Allograft Recipients

  2007cites this paper
• The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide

  2007cites this paper
• Therapeutic drug monitoring of mycophenolic acid.

  2007cites this paper
• Switch to 1.5 grams MMF monotherapy for CNI‐related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension

  2007influential citation
• Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma.

  2007cites this paper
• Therapeutic drug monitoring-based clozapine dosing recommendations.

  2007cites this paper
• Why and How to Perform Therapeutic Drug Monitoring for Mycophenolate Mofetil

  2007cites this paper
• Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?

  2007cites this paper
• Effect of acidification on protein binding of mycophenolic acid.

  2007cites this paper
• Verbesserung der Arzneimittelsicherheit durch Therapiemonitoring

  2007cites this paper
• Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

  2007cites this paper
• Pharmacokinetics and variability of mycophenolic acid from enteric‐coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients

  2007cites this paper
• Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome.

  2007cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients

  2007cites this paper
• C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.

  2007cites this paper
• The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers

  2007cites this paper
• Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post‐transplant

  2006cites this paper
• Nephrotoxizitätsfreie Immunsuppression bei älteren Empfängern von postmortal entnommenen Nieren älterer Organspender - Ergebnisse einer prospektiven Pilotstudie -

  2006cites this paper
• Therapeutic Corner Therapeutic Monitoring of Mycophenolate Mofetil

  2006cites this paper
• Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment

  2006cites this paper
• Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome

  2006cites this paper
• Therapeutic monitoring of mycophenolate mofetil.

  2006cites this paper
• PHARMACOKINETICS OF MYCOPHENOLATE SODIUM AND COMPARISON WITH THE MOFETIL FORMULATION IN KIDNEY TRANSPLANT RECIPIENTS.

  2006cites this paper
• Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature.

  2006cites this paper
• The need of mycophenolic acid monitoring in long‐term renal transplants

  2005cites this paper
• Enteric‐coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil

  2005cites this paper
• Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation

  2005cites this paper
• Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation

  2005cites this paper
• Pharmacokinetics and limited sampling strategies of mycophenolic acid in lung transplant recipients

  2005cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Monitoring for Mycophenolate Mofetil

  2005cites this paper
• "Determination of mycophenolic acid in human plasma by high-performance liquid chromatography"

  2005cites this paper
• Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

  2005cites this paper
• The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation

  2005cites this paper
• Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.

  2005cites this paper
• Monitoraggio dei farmaci immunosoppressori

  2005cites this paper
• Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.

  2005cites this paper
• From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy

  2004cites this paper
• Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients

  2004cites this paper
• Low levels of mycophenolic acid induce differentiation of human neuroblastoma cell lines

  2004cites this paper
• Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy.

  2004cites this paper
• To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription

  2004cites this paper
• Potential Role of Mycophenolate Mofetil in the Management of Neuroblastoma Patients

  2004cites this paper
• Verbesserungen der immunsuppressiven Therapie bei Patienten nach kombinierter Pankreas- und Nierentransplantation

  2004cites this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cites this paper
• Simultaneous determination of free mycophenolic acid and its glucuronide in serum of patients under mycophenolate mophetil therapy by ion-pair reversed-phase liquid chromatography with diode array UV detection.

  2004cites this paper
• New Antiproliferative Immunosuppressive Agents

  2003cites this paper
• Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus.

  2003cites this paper
• Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients.

  2003cites this paper
• Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.

  2003cites this paper
• Effects of Mycophenolate Mofetil on Hematocrit after Renal Transplantation

  2002cites this paper
• Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation.

  2002cites this paper
• Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation

  2002cites this paper